Who You Raise From Matters Most: Interview with Firefly Neuroscience CEO Greg Lipschitz

episode

Scott Nelson Live not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Scott Nelson Live

The Hidden Drivers of Clinical Trial Success: Interview with Rivermark CEO Dr. Adam Kadlec 57 min · 16 Dec 2025

Building the Market Before the Product: Interview with Inmedix CEO Andrew Holman, MD 52 min · 10 Dec 2025

All episodes from Scott Nelson Live →

Report any issue

Source

Recorded29 Jul 2025

Publisherfeeds.transistor.fm ↗

Handlerec:13866207

Show notes

In this episode of Medsider Radio, we sat down with Greg Lipschitz, CEO of Firefly Neuroscience. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology objectively measures brain function through EEG analysis. With a proprietary database spanning twelve cognitive disorders, the company serves both clinical practitioners and pharmaceutical partners.Greg brings extensive experience in private equity, investment banking, capital markets, and finance to his leadership role. As Managing Director of Old Stone Advisors and former Vice President of Lazer Capital, Greg has advised on over $1 billion in transactions. He is a Chartered Financial Analyst.In this interview, Greg shares insights on strategic fundraising approaches, platform prioritization decisions, and building commercial momentum in healthcare through direct sales and customer feedback loops.Before we dive into the discussion, I wanted to mention a few things:First, if you’re into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You’ll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Greg Lipschitz.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.